With a market capitalization (market cap) of $3.19B — a measure of how much the company is worth — NewAmsterdam Pharma Company N.V. is the 1762nd most valuable company in Healthcare as of August 18, 2026. Shares trade at $27.25, up +1.30% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Visit websiteAs of August 18, 2026, NewAmsterdam Pharma Company N.V. (NAMS) is worth $3.19B — this is its market capitalization, the total value of all its outstanding shares.
NewAmsterdam Pharma Company N.V.’s market cap is $3.19B, which ranks it #1762 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
NewAmsterdam Pharma Company N.V. (NAMS) shares trade at $27.25, up 1.30% on the day, as of August 18, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025